Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 6/20 | 1.00 |
| ▸ | PDE4A | P27815 | 4/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.61 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.54 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583450 | 1.00 | PDE4D (1.00) | PDE4DPDE4BPDE4APDE4CSLC5A1 | |
| SCHEMBL2197462 | 0.84 | PDE4B (0.73) | PDE4DPDE4BPDE4APDE4CMEN1 | |
| SCHEMBL7473041 | 0.84 | PDE4B (0.72) | PDE4DPDE4BPDE4APDE4CSLC5A1 | |
| SCHEMBL6070622 | 0.83 | PDE4D (0.76) | PDE4DPDE4BALDH1A1P2RY12NPC1 | |
| SCHEMBL6070321 | 0.82 | PDE4D (0.77) | PDE4DPDE4BMEN1KMT2AALDH1A1 | |
| SCHEMBL2200071 | 0.82 | PDE4D (0.74) | PDE4DPDE4BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6070211 | 0.81 | PDE4D (0.73) | PDE4DPDE4BSMN1; SMN2ALDH1A1P2RY12 | |
| SCHEMBL6069484 | 0.81 | PDE4D (0.72) | PDE4DPDE4BMEN1KMT2AALDH1A1 | |
| SCHEMBL6070540 | 0.81 | PDE4D (0.72) | PDE4DPDE4BALDH1A1P2RY12NPC1 | |
| SCHEMBL10317229 | 0.81 | PDE4B (0.68) | PDE4DPDE4BPDE4APDE4CSLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | claimed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | claimed |
| EP-1248781-A1 | PYRAZOLE CYCLIC AMP-SPECIFIC PDE INHIBITORS | ICOS CORPORATION (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001046172-A1 | PYRAZOLE CYCLIC AMP-SPECIFIC PDE INHIBITORS | ICOS CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110223166-A1 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death | MINAS THEODORE CORONEO (AU) | 2011-09-15 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060013814-A1 | Methods for preventing pressure-induced apoptotic neural-cell death | DAVIES COLLISON CAVE (AU) | 2006-01-19 | — | — | US | disclosed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | PDE4D 814/4885PDE4B 607/4885PDE4A 762/4885 |
| US-20060013814-A1 | Methods for preventing pressure-induced apoptotic neural-cell death | BAX, CASP3, BCL2 | PDE4D 2380/4885PDE4B 2188/4885PDE4A 2017/4885 |
| US-20110223166-A1 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death | BAX, CASP3, BCL2 | PDE4D 2380/4885PDE4B 2188/4885PDE4A 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.